Arecor Therapeutics PLC APPOINTS DR. LINDSEY FOULKES AS COO
10 June 2021 - 4:00PM
RNS Non-Regulatory
TIDMAREC
Arecor Therapeutics PLC
10 June 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING
OFFICER
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM:
AREC), a globally focused biopharmaceutical company advancing
today's therapies to enable healthier lives, today announces the
appointment of Dr. Lindsey Foulkes as the Company's Chief Operating
Officer.
Lindsey brings a wealth of deep expertise and experience from
the life science industry, with roles covering strategy, marketing,
project management and corporate development. Having completed a
PhD in Immunology, she started her commercial career in consultancy
with McKinsey & Company in 1995 before moving to help establish
Nexan Ltd, a medical device start-up. She has also worked in
commercial roles at Acambis plc, a vaccine development company, and
Cangene Corporation, an immune therapeutics company where she led
Strategic Business Development from 2007-2011. Lindsey then worked
as a freelance consultant, working with academic groups and
companies across the biotech and pharmaceutical fields. In 2016 she
joined Liminal Biosciences (previously known as Prometic), a Nasdaq
listed multinational company focusing on rare diseases, where she
was Senior Director of Business Development. At Liminal, she also
managed major organisational changes, including steering the
company's late-stage clinical programmes. Lindsey joins the
Executive team at Arecor.
Sarah Howell, Chief Executive Officer of Arecor, said: "We're
thrilled that Lindsey is joining Arecor's Executive team as we
enter our next phase of growth. Lindsey will play a key role in
ensuring that we deliver on the key strategic goals that we set out
at the time of our recent IPO. She brings extensive experience from
across the innovative healthcare sector which will significantly
strengthen our commercial and operational capabilities as we
advance our internal proprietary pipeline and further expand our
partnered portfolio."
Lindsey Foulkes, of Arecor, said: "Arecor's innovative
Arestat(TM) technology has been validated through multiple
partnerships with major pharmaceutical and biotechnology companies,
as well as through the best-in-class clinical data achieved for its
lead insulin programme AT247. I'm excited to be joining the Company
as it scales up and look forward to working with the team to
deliver the benefits of Arecor's ability to enhance medicines to
pharmaceutical partners and, ultimately, to patients."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited
(NOMAD and Broker)
Freddy Crossley, Emma Earl Tel: +44 (0) 20 7886 2500
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Tel: +44 (0) 20 3709 5700
Angela Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company
transforming patient care by bringing innovative medicines to
market. Through the enhancement of existing medicines using our
Arestat(TM) technology, we are developing a broad portfolio of
therapies as part of our proprietary pipeline and through
partnerships with leading pharmaceutical and biotech companies. Our
treatments for people living with chronic disease are designed to
simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKLLBFQLLBBB
(END) Dow Jones Newswires
June 10, 2021 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024